Harvard Bioscience Inc (HBIO) - Total Liabilities
Based on the latest financial reports, Harvard Bioscience Inc (HBIO) has total liabilities worth $63.92 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Harvard Bioscience Inc operating cash flow efficiency to assess how effectively this company generates cash.
Harvard Bioscience Inc - Total Liabilities Trend (1998–2024)
This chart illustrates how Harvard Bioscience Inc's total liabilities have evolved over time, based on quarterly financial data. Check how resilient are Harvard Bioscience Inc's assets to evaluate the company's liquid asset resilience ratio.
Harvard Bioscience Inc Competitors by Total Liabilities
The table below lists competitors of Harvard Bioscience Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Grand Kartech Tbk
JK:KRAH
|
Indonesia | Rp563.69 Billion |
|
Hankook Cosmetics Manufacturing Co Ltd
KO:003350
|
Korea | ₩48.22 Billion |
|
Canadian North Resources Inc.
V:CNRI
|
Canada | CA$2.98 Million |
|
Seker Finansal Kiralama AS
IS:SEKFK
|
Turkey | TL3.98 Billion |
|
Rubicon Organics Inc
V:ROMJ
|
Canada | CA$19.46 Million |
|
Murray International Trust
LSE:MYI
|
UK | GBX112.39 Million |
|
Aasen Sparebank
OL:AASB
|
Norway | Nkr6.22 Billion |
Liability Composition Analysis (1998–2024)
This chart breaks down Harvard Bioscience Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Harvard Bioscience Inc (HBIO) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.81 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 4.54 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.82 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Harvard Bioscience Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Harvard Bioscience Inc (1998–2024)
The table below shows the annual total liabilities of Harvard Bioscience Inc from 1998 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $63.30 Million | -1.54% |
| 2023-12-31 | $64.29 Million | -12.10% |
| 2022-12-31 | $73.14 Million | -7.35% |
| 2021-12-31 | $78.94 Million | -0.79% |
| 2020-12-31 | $79.57 Million | -4.33% |
| 2019-12-31 | $83.18 Million | -3.16% |
| 2018-12-31 | $85.89 Million | +201.85% |
| 2017-12-31 | $28.45 Million | -20.00% |
| 2016-12-31 | $35.57 Million | -16.54% |
| 2015-12-31 | $42.62 Million | +5.37% |
| 2014-12-31 | $40.45 Million | -1.29% |
| 2013-12-31 | $40.98 Million | +39.98% |
| 2012-12-31 | $29.27 Million | -5.99% |
| 2011-12-31 | $31.14 Million | -9.88% |
| 2010-12-31 | $34.55 Million | +8.05% |
| 2009-12-31 | $31.97 Million | +119.71% |
| 2008-12-31 | $14.55 Million | -41.12% |
| 2007-12-31 | $24.72 Million | +15.79% |
| 2006-12-31 | $21.34 Million | -9.63% |
| 2005-12-31 | $23.62 Million | -33.51% |
| 2004-12-31 | $35.52 Million | +20.21% |
| 2003-12-31 | $29.55 Million | +53.89% |
| 2002-12-31 | $19.20 Million | +23.49% |
| 2001-12-31 | $15.55 Million | +140.20% |
| 2000-12-31 | $6.47 Million | -48.73% |
| 1999-12-31 | $12.63 Million | +93.00% |
| 1998-12-31 | $6.54 Million | -- |
About Harvard Bioscience Inc
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States, Germany, and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equ… Read more